Allergan Botox increase could provide incremental upside, says Credit Suisse Credit Suisse said Allergan's first price in six years for Botox could lead to incremental upside to Street estimates. The firm expects 2014 guidance to be a catalyst for shares and raised estimates and price target to $123 from $112. Shares are Outperform rated.
News For AGN From The Last 14 Days
Check below for free stories on AGN the last two weeks.